Physician profile
Michael Steven Cole
NPI 1710973649
$6,369.61
in general payments reported to CMS, 2019-2025
39 companies · $492 in 2025
The $492 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $892 · 2020: $669 · 2021: $369 · 2022: $1,073 · 2023: $1,340 · 2024: $1,535 · 2025: $492.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,367.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,367.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $856.14 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $751.45 | 2021-2024 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $617.64 | 2019-2025 | Rybelsus, Ozempic |
| Pfizer INC. | $543.34 | 2019-2025 | |
| Lilly USA, LLC | $447.25 | 2020-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $321.76 | 2019-2025 | Evenity, Prolia, Repatha |
| Glaxosmithkline, LLC. | $238.54 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Allergan, INC. | $230.99 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $201.61 | 2020-2024 | Xarelto |
| Supernus Pharmaceuticals, INC. | $181.18 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $179.30 | 2023-2024 | Rexulti |
| Abbott Laboratories | $140.59 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.59 | 2019-2025 | Xifaxan, Trulance |
| Procept Biorobotics Corporation | $133.93 | 2023 | Aquabeam Robotic System |
| Bayer Healthcare Pharmaceuticals INC. | $119.98 | 2021-2024 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.76 | 2022-2024 | Caplyta |
| Antares Pharma, INC. | $110.93 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $102.57 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.16 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $91.90 | 2024 | Voquezna |
| Merck Sharp & Dohme LLC | $83.17 | 2019-2025 | Capvaxive, Gardasil 9, Proquad |
| Exact Sciences Corporation | $80.61 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $76.91 | 2019-2024 | Veozah |
| Sanofi-Aventis U.S. LLC | $64.45 | 2019-2024 | |
| Xeris Pharmaceuticals, INC. | $62.47 | 2023-2025 | Gvoke Hypopen |
| Dexcom, INC. | $61.41 | 2024-2025 | Dexcom G6 Transmitter |
| Amarin Pharma, INC. | $59.13 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.88 | 2022 | |
| Sanofi Pasteur INC. | $36.47 | 2022-2023 | |
| Abiomed | $32.94 | 2024 | Impella |
| Idorsia Pharmaceuticals US INC | $22.52 | 2022 | |
| Biogen, INC. | $19.46 | 2024 | Skyclarys |
| Currax Pharmaceuticals LLC | $17.27 | 2023 | Nexlizet, Nexletol, Contrave |
| Kowa Pharmaceuticals America, INC. | $17.23 | 2023 | Seglentis |
| Sumitomo Pharma America, INC. | $16.30 | 2024 | Gemtesa |
| Alfasigma USA, INC. | $14.75 | 2022 | |
| Verona Pharma, INC. | $14.75 | 2025 | Ohtuvayre |
| Biohaven Pharmaceuticals, INC. | $12.06 | 2020 | |
| Genentech USA, INC. | $11.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.